A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Inclusion Criteria: * Age≥18 years old, gender is not limited; * Confirmed by histopathological or cytological diagnosis of pancreatic cancer; * Underwent surgical resection of the pancreas for non-metastatic pancreatic cancer (including resectable/borderline resectable pancreatic cancer, or locally advanced pancreatic cancer); * Received Nimotuzumab plus adjuvant chemotherapy or adjuvant chemotherapy alone after surgery. Exclusion Criteria: * Patients with other primary malignancies other than pancreatic cancer; * Evidence of recurrence or distant metastasis before surgery * Received immunotherapy drugs (such as PD-1 inhibitors, etc.) used during adjuvant therapy, or proprietary Chinese medicines with anti-tumor indications, or hyperthermia, targeted therapy drugs other than nimotuzumab; * Key information is missing (e.g., primary endpoint data were not available).